Shares

6 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2019

Nov 01, 2019

SELL
$16.91 - $36.27 $157,076 - $336,912
-9,289 Closed
0 $0
Q2 2019

Jul 26, 2019

SELL
$31.0 - $36.3 $47,058 - $55,103
-1,518 Reduced 14.05%
9,289 $331,000
Q4 2018

Feb 01, 2019

BUY
$30.43 - $56.65 $1,186 - $2,209
39 Added 0.36%
10,807 $355,000
Q3 2018

Oct 25, 2018

BUY
$46.46 - $68.49 $87,577 - $129,103
1,885 Added 21.22%
10,768 $656,000
Q2 2018

Jul 20, 2018

BUY
$46.25 - $104.45 $230,602 - $520,787
4,986 Added 127.94%
8,883 $434,000
Q1 2018

Apr 18, 2018

BUY
$57.4 - $108.44 $223,687 - $422,590
3,897 New
3,897 $414,000

Others Institutions Holding NKTR

About NEKTAR THERAPEUTICS


  • Ticker NKTR
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 187,404,992
  • Market Cap $191M
  • Description
  • Nektar Therapeutics, a biopharmaceutical company, focuses on discovering and developing medicines in areas of unmet medical need in the United States and internationally. The company's products include Bempegaldesleukin, a CD122-preferential interleukin-2 (IL-2) pathway agonist, which is in phase 3 clinical trial to treat metastatic melanoma, re...
More about NKTR
Track This Portfolio

Track Creative Planning Portfolio

Follow Creative Planning and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Creative Planning, based on Form 13F filings with the SEC.

News

Stay updated on Creative Planning with notifications on news.